ctDNA在妇科恶性肿瘤诊治中的研究进展
Research Progress of Circulating Tumor DNA in the Diagnosis and Treatment of Gynecological Malignant Tumors
DOI: 10.12677/ACM.2024.141021, PDF,   
作者: 木尼热克孜·木塔力甫:新疆医科大学研究生院,新疆 乌鲁木齐;韩莉莉*:新疆维吾尔自治区人民医院妇科,新疆 乌鲁木齐
关键词: 循环肿瘤DNA筛查诊断治疗预后Circulating Tumor DNA Screening Diagnosis Treat Prognosis
摘要: 妇科中宫颈癌、卵巢癌和子宫内膜癌是女性生殖系统常见的恶性肿瘤,严重危害妇女健康。卵巢癌仍然是妇科恶性肿瘤中最致命的疾病,发病率逐年上升。对于这种恶性肿瘤来说提高早期诊断水平、争取治疗时机至关重要。我国妇科恶性肿瘤死亡率较高,主要的原因在于我国缺乏早期筛查、诊断方法,而当发现时多数患者已处于中晚期。目前在妇科恶性肿瘤早期检测和筛查、复发监测、治疗评估方面尚缺乏有效的检测手段。循环肿瘤DNA (circulating tumor DNA, ctDNA)是提供微创样本采集的主要液体活检方法。在许多类型的实体恶性肿瘤中都显示出诊断、预后和预测价值,最近的研究试图阐明它们在卵巢癌中的作用。本文对ctDNA的生物特性以及在妇科恶性肿瘤早期诊断与筛查、疗效评价、预测复发转移检测等方面进行综述。
Abstract: Cervical, ovarian and endometrial cancers are common malignant tumors of the female reproduc-tive system, which seriously endanger women’s health. Ovarian cancer remains the most lethal disease of gynecologic malignancies, and the incidence is increasing year by year. For this malignant tumor, it is important to improve the level of early diagnosis and strive for treatment time. The mortality rate of gynecological malignant tumors in China is relatively high, mainly due to the lack of early screening and diagnosis methods in China, and when it is found, most patients are in the middle and advanced stages. At present, there is a lack of effective detection methods for early de-tection and screening, recurrence monitoring, and treatment evaluation of gynecological malignant tumors. Circulating tumor DNA (ctDNA) is the primary liquid biopsy method that provides mini-mally invasive sample collection. They have shown diagnostic, prognostic, and predictive value in many types of solid malignancies, and recent studies have attempted to elucidate their role in ovarian cancer. This article introduces the biological characteristics of ctDNA and reviews its early diagnosis and screening of gynecological malignant tumors, efficacy evaluation, and prediction of recurrence and metastasis.
文章引用:木尼热克孜·木塔力甫, 韩莉莉. ctDNA在妇科恶性肿瘤诊治中的研究进展[J]. 临床医学进展, 2024, 14(1): 142-147. https://doi.org/10.12677/ACM.2024.141021

参考文献

[1] Charo, L.M., et al. (2021) Clinical Implications of Plasma Circulating Tumor DNA in Gynecologic Cancer Patients. Mo-lecular Oncology, 15, 67-79. [Google Scholar] [CrossRef] [PubMed]
[2] Yang, F., Tang, J., Zhao, Z.H., Zhao, C.L. and Xiang, Y.C. (2021) Circulating Tumor DNA: A Noninvasive Biomarker for Tracking Ovarian Cancer. Repro-ductive Biology and Endocrinology, 19, Article No. 178. [Google Scholar] [CrossRef] [PubMed]
[3] Pessoa, L.S., Heringer, M. and Ferrer, V.P. (2020) ctDNA as a Cancer Biomarker: A Broad Overview. Critical Reviews in Oncology/Hematology, 155, Article ID: 103109. [Google Scholar] [CrossRef] [PubMed]
[4] Campos-Carrillo, A., et al. (2020) Circulating Tumor DNA as an Early Cancer Detection Tool. Pharmacology & Therapeutics, 207, Article ID: 107458. [Google Scholar] [CrossRef] [PubMed]
[5] Stroun, M., et al. (1989) Neoplastic Characteristics of the DNA Found in the Plasma of Cancer Patients. Oncology, 46, 318-322. [Google Scholar] [CrossRef] [PubMed]
[6] Mouliere, F., et al. (2011) High Fragmentation Characterizes Tu-mour-Derived Circulating DNA. PLOS ONE, 6, e23418. [Google Scholar] [CrossRef] [PubMed]
[7] Underhill, H.R., et al. (2016) Fragment Length of Circulating Tumor DNA. PLOS Genetics, 12, e1006162. [Google Scholar] [CrossRef] [PubMed]
[8] Keller, L., Belloum, Y., Wikman, H. and Pantel, K. (2021) Clin-ical Relevance of Blood-Based ctDNA Analysis: Mutation Detection and Beyond. British Journal of Cancer, 124, 345-358. [Google Scholar] [CrossRef] [PubMed]
[9] Burrell, R.A., McGranahan, N., Bartek, J. and Swan-ton, C. (2013) The Causes and Consequences of Genetic Heterogeneity in Cancer Evolution. Nature, 501, 338-345. [Google Scholar] [CrossRef] [PubMed]
[10] Sokoll, L., et al. (2008) Circulating Mutant DNA to Assess Tumor Dy-namics. Nature Medicine, 14, 985-990. [Google Scholar] [CrossRef] [PubMed]
[11] Weber, S., et al. (2020) Technical Evaluation of Commercial Mutation Anal-ysis Platforms and Reference Materials for Liquid Biopsy Profiling. Cancers, 12, Article 1588. [Google Scholar] [CrossRef] [PubMed]
[12] Romero, A., et al. (2021) Comprehensive Cross-Platform Compari-son of Methods for Non-Invasive EGFR Mutation Testing: Results of the RING Observational Trial. Molecular Oncol-ogy, 15, 43-56. [Google Scholar] [CrossRef] [PubMed]
[13] Jie, X., et al. (2022) Mutation Analysis of Circulating Tumor DNA and Paired Ascites and Tumor Tissues in Ovarian Cancer. Experimental and Therapeutic Medicine, 24, Article No. 542. [Google Scholar] [CrossRef] [PubMed]
[14] Raymond, V.M., Higashi, L., Marino, E. and Lang, K. (2021) Evalua-tion of the ctDNA LUNAR-2 Test In an Average Patient Screening Episode (ECLIPSE). Journal of Clinical Oncology, 39, TPS142-TPS142. [Google Scholar] [CrossRef
[15] Rolfo, C., et al. (2020) Challenges and Opportunities of cfDNA Analysis Implementation in Clinical Practice: Perspective of the International Society of Liquid Biopsy (ISLB). Critical Reviews in Oncology/Hematology, 151, Article ID: 102978. [Google Scholar] [CrossRef] [PubMed]
[16] Bettegowda, C., et al. (2014) Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 6, 224ra24.
[17] Maritschnegg, E., et al. (2015) Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study. Journal of Clinical Oncology, 33, 4293-4300. [Google Scholar] [CrossRef
[18] Zhou, J., et al. (2015) Urinary microRNA-30a-5p Is a Potential Biomarker for Ovarian Serous Adenocarcinoma. Oncology Reports, 33, 2915-2923. [Google Scholar] [CrossRef] [PubMed]
[19] Lukasiewicz, M., et al. (2021) Diagnostic Accuracy of Liq-uid Biopsy in Endometrial Cancer. Cancers, 13, Article 5731. [Google Scholar] [CrossRef] [PubMed]
[20] Bolivar, A.M., et al. (2019) Targeted Next-Generation Sequencing of Endometrial Cancer and Matched Circulating Tumor DNA: Identification of Plasma-Based, Tumor-Associated Muta-tions in Early Stage Patients. Modern Pathology, 32, 405-414. [Google Scholar] [CrossRef] [PubMed]
[21] Veyer, D., et al. (2020) HPV Circulating Tumoral DNA Quanti-fication by Droplet-Based Digital PCR: A Promising Predictive and Prognostic Biomarker for HPV-Associated Oropha-ryngeal Cancers. International Journal of Cancer, 147, 1222-1227. [Google Scholar] [CrossRef] [PubMed]
[22] Jeannot, E., et al. (2016) Circulating Human Papillomavirus DNA Detected Using Droplet Digital PCR in the Serum of Patients Diagnosed with Early Stage Human Papillomavirus-Associated Invasive Carcinoma. The Journal of Pathology: Clinical Research, 2, 201-209. [Google Scholar] [CrossRef] [PubMed]
[23] Damerla, R.R., et al. (2019) Detection of Early Human Papillomavirus-Associated Cancers by Liquid Biopsy. JCO Precision Oncology, 3, 1-11. [Google Scholar] [CrossRef
[24] Kang, Z., Stevanović, S., Hinrichs, C.S. and Cao, L. (2017) Circulating Cell-Free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring. Clinical Cancer Research, 23, 6856-6862. [Google Scholar] [CrossRef
[25] Marsavela, G., et al. (2022) Detection of Clinical Progres-sion through Plasma ctDNA in Metastatic Melanoma Patients: A Comparison to Radiological Progression. British Jour-nal of Cancer, 126, 401-408. [Google Scholar] [CrossRef] [PubMed]
[26] Reece, M., et al. (2019) The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer. Frontiers in Genetics, 10, Article 482516. [Google Scholar] [CrossRef] [PubMed]
[27] Yi, X., et al. (2017) The Feasibility of Using Mutation Detection in ctDNA to Assess Tumor Dynamics. International Journal of Cancer, 140, 2642-2647. [Google Scholar] [CrossRef] [PubMed]
[28] Kidess, E., et al. (2015) Mutation Profiling of Tumor DNA from Plasma and Tumor Tissue of Colorectal Cancer Patients with A novel, High-Sensitivity Multiplexed Mutation Detection Platform. Oncotarget, 6, 2549-2561. [Google Scholar] [CrossRef] [PubMed]
[29] Zhu, J.W., et al. (2023) Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer. International Journal of Molecular Sciences, 24, Article 14388. [Google Scholar] [CrossRef] [PubMed]
[30] Hou, J.Y., et al. (2022) Circulating Tumor DNA Monitoring for Early Recurrence Detection in Epithelial Ovarian Cancer. Gynecologic Oncology, 167, 334-341. [Google Scholar] [CrossRef] [PubMed]
[31] Campitelli, M., et al. (2012) Human Papillomavirus Mutational Insertion: Specific Marker of Circulating Tumor DNA in Cervical Cancer Patients. PLOS ONE, 7, e43393. [Google Scholar] [CrossRef] [PubMed]
[32] Gadducci, A., Tana, R., Cosio, S. and Genazzani, A.R. (2008) The Serum Assay of Tumour Markers in the Prognostic Evaluation, Treatment Monitoring and Follow-Up of Patients with Cervical Cancer: A Review of the Literature. Critical Reviews in Oncology/Hematology, 66, 10-20. [Google Scholar] [CrossRef] [PubMed]
[33] Sharbatoghli, M., et al. (2020) Prediction of the Treatment Response in Ovarian Cancer: A ctDNA Approach. Journal of Ovarian Research, 13, Article No. 124. [Google Scholar] [CrossRef] [PubMed]